DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Sheppard M, Bronstein MD, Freda P. et al.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Pituitary 2014;
18: 385-394
We do not assume any responsibility for the contents of the web pages of other providers.